{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(5)"],"submitter":["Rikken SAOF"],"funding":["CSL Behring LLC"],"pubmed_abstract":["<h4>Background</h4>The AEGIS-II (ApoA-I Event Reducing in Ischemic Syndromes-II; NCT03473223) trial evaluated CSL112, a human plasma-derived apolipoprotein A-I therapy, for reducing cardiovascular events after acute myocardial infarction (AMI). Given CSL112's potential anti-inflammatory properties, we conducted an exploratory post hoc analysis to determine if its efficacy is influenced by baseline neutrophil-lymphocyte ratio (NLR), a marker of systemic inflammation, and low-density lipoprotein cholesterol (LDL-C).<h4>Objectives</h4>The purpose of this study was to investigate the association of baseline NLR and cardiovascular events and explore whether NLR and LDL-C modify CSL112's efficacy in post-AMI patients.<h4>Methods</h4>A total of 18,219 participants with AMI, multivessel coronary a"],"journal":["JACC. Advances"],"pagination":["101727"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12059331"],"repository":["biostudies-literature"],"pubmed_title":["Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels."],"pmcid":["PMC12059331"],"pubmed_authors":["Korjian S","Steg PG","White H","van 't Hof AWJ","Mahaffey KW","AEGIS-II Committees and Investigators","Cornel JH","Chi G","Anschuetz G","Duffy D","Goodman SG","Ten Berg JM","Nicholls SJ","Lopes RD","Kingwell BA","Gibson CM","Bahit MC","Mehran R","Ridker PM","Rikken SAOF","Ophuis TO","Bainey KR","Harrington RA","Nicolau JC","Lewis BS","Vinereanu D","Libby P","Mohammadnia N","Bode C","El Messaoudi S"],"additional_accession":[]},"is_claimable":false,"name":"Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.","description":"<h4>Background</h4>The AEGIS-II (ApoA-I Event Reducing in Ischemic Syndromes-II; NCT03473223) trial evaluated CSL112, a human plasma-derived apolipoprotein A-I therapy, for reducing cardiovascular events after acute myocardial infarction (AMI). Given CSL112's potential anti-inflammatory properties, we conducted an exploratory post hoc analysis to determine if its efficacy is influenced by baseline neutrophil-lymphocyte ratio (NLR), a marker of systemic inflammation, and low-density lipoprotein cholesterol (LDL-C).<h4>Objectives</h4>The purpose of this study was to investigate the association of baseline NLR and cardiovascular events and explore whether NLR and LDL-C modify CSL112's efficacy in post-AMI patients.<h4>Methods</h4>A total of 18,219 participants with AMI, multivessel coronary a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T05:23:25.707Z","creation":"2026-04-08T09:36:12.868Z"},"accession":"S-EPMC12059331","cross_references":{"pubmed":["40288083"],"doi":["10.1016/j.jacadv.2025.101727"]}}